The prospectus is expected to be published on 20 March 2017 and the first day of trading on First North Premier is planned for 4 April 2017. The subscription price in the offer is SEK 29 per share, which corresponds to a value of Isofol of approximately MSEK 487 prior to the offer.
Isofol is an oncology company which clinically develops Modufolin which is a first choice medicament in conjunction with treatment of spread colorectal cancer and is standard therapy in conjunction with high dosage treatment with metotrexat of osteosarcoma. Isofol thus intends to replace the existing folate-based medicaments leukovorin and levoleukovorin, which are currently considered to be the standard treatment within these treatment areas.
Through a worldwide, exclusive license agreement Isofol Medical holds all rights to a global commercialization of Modufolin for cancer treatment as well as access to Merck KGaA’s (Darmstadt, Germany) patent-protected manufacturing process and production capacity.
Vinge’s team primarily consisted of responsible partner Anders Strid, partners Jesper Schönbeck and Magnus Pauli, associates Frida Bäckegren, Natalie Bäck, Petronella Hallberg, Victor Ericsson and company assistant Camilla Andersson.